Current Setup & Catalysts

Current Setup & Catalysts

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

The stock is trading around $18.22 (21 May 2026), up roughly 94% in a single month and 154% over the trailing year, and the market is mostly watching whether the China-driven order book disclosed since November 2025 actually converts to cash in the Q2 and Q3 FY2026 quarterly filings. The recent setup is bullish on tape and bookings, bearish on the underlying thesis variables — six months of strong DART supply contracts and a $4.5M controlling-shareholder injection have already been priced, while the FY2025 cash conversion gap, the FY2024 PP&E reclassification, and the 56.5% YILINING customer concentration remain unresolved. The near-term calendar is unusually rich for a microcap: a 5-for-1 forward stock split on 2026-07-27 is hard-dated 66 days away, a Q2 FY2026 quarterly business report follows in mid-August, and the prospective CXMT IPO sits inside the window as the single biggest external lever on the YILINING/Yiling Trading order chain. This page is the bridge from the durable thesis page to the events that actually update it over the next two quarters.

What Changed in the Last 3-6 Months

The post-November 2025 stretch is the spine of the current setup. Eight events deserve the PM's attention because they either changed the order book, the capital structure, or the market's read of the controlling-shareholder behaviour.

The recent narrative arc. Six months ago the market worried about whether Mirae could survive another FY2023-class trough — the share count had nearly tripled to 4.47M (post the July 2025 16:1 reverse split), cash was at a five-year low, and there was no third-party validation of the customer story. Two things changed that: the November 2025 $9.7M contract published in DART crystallised the China order book as a discrete event chain, and the January 2026 Nextern Roll Korea $4.5M injection removed the acute funding question. What investors are now arguing about is no longer survival — it is whether the FY2025 print is a single-cycle artifact priced at peer multiples or the start of a structural earnings step-up. The unresolved item across the whole post-November stretch is cash conversion: every single forward variable (capex normalization, dividend optionality, lendability of the controller, ability to absorb another customer pause without dilution) flows through whether reported earnings of $7M can pay out as $5-6M of operating cash in any rolling twelve-month window.

What the Market Is Watching Now

The five debates rank in declining order of decision value. Cash conversion in Q2 sits at the top because every other variable — capital allocation, dilution risk, sustainability of the China relationship, ability to weather a customer pause — eventually flows through it. CXMT IPO is the highest-value external variable because Mirae's name on the Korean supplier list is the closest thing to third-party validation of the durable revenue case. BIS is binary and asymmetric — the highest-severity tail risk, but the least useful to track day-to-day.

Ranked Catalyst Timeline

Eight events with enough date precision and thesis linkage to belong on a PM's near-term board. Ranked by decision value, not chronology.

The ranking deliberately puts the Q2 FY2026 cash flow print ahead of CXMT because the cash test is observable on a definite date and resolves the most contested bear point in the file. CXMT is higher impact in magnitude but lower confidence — a delayed IPO is a non-event for Mirae's FY2026 revenue line, since shipments are already booked. BIS sits at #3 for severity but with a Low confidence on timing; a PM should monitor it as a tail rather than time it. Items #5-8 update the long-term thesis but are second-order to the cash and customer questions.

Impact Matrix

The catalysts that genuinely resolve underwriting questions, not just add information.

Four of the five rows in the matrix update durable thesis variables, not just the near-term print. That is unusual for a microcap — most catalyst pages are stuffed with single-quarter events. For Mirae, the events that matter on a six-month horizon are also the events that matter on a five-year horizon, because the company is small enough that any single one of these resolutions can rewrite the entire underwriting model. The Q2 cash flow turn is the closest to an "atomic" thesis test in the file: a clean print refutes three forensic flags simultaneously (B4 capitalising opex, C2 op outflows in investing, C4 working-capital lifelines), and a bad print confirms all three at once.

Next 90 Days

The window from today (2026-05-22) through late August 2026.

The 90-day calendar is dense, not thin. Two hard dates inside the window (split + Q2 print) and three rolling watchpoints (DART cadence, CXMT, BIS) is more catalyst content than most KOSDAQ microcaps carry in a quarter. The asymmetry sits in the Q2 print: a clean OCF turn could justify a starter long even at the current parabolic tape; a missed print would invalidate the bull case before any other variable has a chance to update.

What Would Change the View

Three observable signals over the next six months would change the investment debate more than any other. First, a positive Q2 FY2026 OCF print in the August quarterly filing — that single number would refute the cleanest forensic short thesis (B4 capitalising opex / C2 op outflows in investing / C4 working-capital lifelines all at once) and convert the FY2025 P&L from a single-cycle artifact into the start of a structural earnings base. Second, a CXMT IPO prospectus that names Mirae or Yiling Trading as a contracted equipment supplier — the long-term thesis on customer durability rests on a relationship the company itself has only ever confirmed through one DART supply contract; external validation removes the "one customer, one year" framing the bear case depends on. Third, any BIS Federal Register notice or Korean MOTIE statement that expands controls to back-end test equipment shipped to YMTC / CXMT / Yiling-adjacent customers — this is the binary, uncorrelated tail risk that nothing else in the file offsets, and a single ruling can reverse 56.5% of FY2025 revenue inside one quarter. The first two would force a re-rating toward the bull case ($26.4-29.7 target band); the third would force a re-rating toward the bear case ($7.92 target band). The current price of $18.22 sits between them because none of the three has yet printed — but all three have observable evidence windows inside the next six months, which makes the position size question a function of which signal a PM is willing to wait for.